- Home
- SER vs NAAS Comparison
SER vs NAAS Comparison
Compare SER & NAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SER | NAAS |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4M | 50.8M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SER | NAAS |
|---|---|---|
| Price | $1.44 | $1.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 71.2K | 20.8K |
| Earning Date | 11-24-2026 | 11-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $130,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.14 | N/A |
| 52 Week Low | $1.14 | $1.45 |
| 52 Week High | $4.26 | $4.10 |
Technical Indicators
Market Signals| Indicator | SER | NAAS |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 28.44 |
| Support Level | $1.38 | N/A |
| Resistance Level | $2.13 | $3.39 |
| Average True Range (ATR) | 0.31 | 0.35 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 17.73 | 8.65 |
Price Performance
Historical ComparisonAbout SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.